Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Summit plc
Summit plc
Activities:
Manufacturing
Ingredients
Research & Development
Infection Control
Pharmaceutical
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Summit appoints Dr David Roblin as Chief Medical Officer
Roblin has been involved in the successful development of a number of important medicines in a range of therapy areas
Research & Development
Wellcome Trust awards Summit £4m to further develop C. Difficile antibiotic
Phase I trial to start by end of the year with results expected in first half of 2013
Research & Development
Summit agrees technology licence with Bristol-Myers Squibb
Summit will receive $100,000 fee for access to its Seglin technology
Manufacturing
Cambridge Major Labs supports Summit antibiotic project
The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Subscribe now